NCI Drug Dictionary
The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
A combination preparation of 1:1 mixture of the immunotoxins HD37-dgA and RFB4-dgA with potential antineoplastic activity. Anti-CD19 IgG monoclonal antibody HD37 and anti-CD22 IgG monoclonal antibody RFB4 are attached individually to a deglycosylated ricin A chain (dgA) via N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio) toluene (SMPT) linker. Deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins bind to CD19- and CD22-expressing tumor cells, specifically delivering cytotoxic ricin A chain to leukemia cells expressing these antigens. Ricin A chain is toxic to ribosomal activity and protein synthesis, and inhibits cell growth. CD19 and CD22 molecules are cell surface antigens present on the majority of B acute lymphoblastic leukemia (ALL) cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|US brand name:||Combotox|